The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Managing Patients Treated with Bevacizumab Combination Therapy
Abstract
The anti-angiogenic agent bevacizumab (Avastin®) has been rationally designed to target vascular endothelial growth factor (VEGF), a key mediator of tumor angiogenesis. Based on its limited roles in adults, VEGF inhibition using bevacizumab would be expected to have limited side effects. Furthermore, because its mechanism of action is different to that of standard chemotherapeutic agents, bevacizumab would not be expected to cause typical cytotoxic agent-related toxicity or to exacerbate the toxicity of concomitant chemotherapy. We have reviewed clinical trials published to date, primarily in metastatic colorectal cancer, and describe the safety profile of bevacizumab. The review focuses on hypertension, proteinuria, arterial thrombosis, effects on wound healing, bleeding and gastrointestinal (GI) perforation, which are the principal bevacizumab-related events seen in clinical trials. These events are for the most part mild to moderate in severity and clinically manageable (hypertension, proteinuria, minor bleeding) or occur uncommonly (wound healing complications, GI perforations and arterial thrombosis). The side-effect profile of bevacizumab makes it a suitable adjunct to standard chemotherapy in settings where efficacy has been demonstrated, and it is now approved for use in the USA, the European Union and other markets worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Self-citationVEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 699
FERRARA, N. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70064-x · Cited by 623
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., Hainsworth, J. D., Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S., & Hurwitz, H. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20301 · Cited by 537
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 364
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., & Kerbel, R. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1589 · Cited by 333
Ross, J. A., Oeffinger, K. C., Davies, S. M., Mertens, A. C., Langer, E. K., Kiffmeyer, W. R., Sklar, C. A., Stovall, M., Yasui, Y., & Robison, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.152 · Cited by 139
Bevacizumab for Patients with Metastatic Renal Cancer
Yang, J. C.-H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050006 · Cited by 128
Skillings, J. R., Johnson, D. H., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Holmgren, E. B., Holden, S. N., Hurwitz, H. I., & Scappaticci, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3019 · Cited by 95
Epidemiology and management of venous thromboembolism in patients with cancer
Lee, A. Y. Y. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00347-5 · Cited by 78
Oxaliplatin: A Review of its Use in Combination Therapy for Advanced Metastatic Colorectal Cancer
Simpson, D., Dunn, C. J., Curran, M. P., & Goa, K. L. (2003) · Drugs · doi:10.2165/00003495-200363190-00013 · Cited by 73
Dupont, J., Schwartz, L., Koutcher, J. A., Spriggs, D. R., Gordon, M. S., Mendelson, D. S., Murren, J., Lucarelli, A., & Cedarbaum, J. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3009 · Cited by 56
Self-citationExpanding the Clinical Development of Bevacizumab
Chen, H. X. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-27 · Cited by 37
MASS, R. D., Fyfe, G., Hambleton, J., Kabbinavar, F. F., Hurwitz, H. I., Novotny, W. F., & Sarkar, S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3616 · Cited by 22
Kozloff, M., Cohn, A. L., Christiansen, N., Flynn, P. J., Kabbinavar, F. F., Robles, R., Yood, M. U., Sarkar, S., Hambleton, J., & Grothey, A. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3566 · Cited by 21
Optimal use of the combination of irinotecan and 5-fluorouracil
BENSONIII, A., & Goldberg, R. M. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70027-x · Cited by 17
Cited by
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer
Kong, D.-H., Kim, Y., Kim, M., Jang, J., & Lee, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041057 · Cited by 683
Zhu, X., Wu, S., Dahut, W. L., & Parikh, C. R. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.11.039 · Cited by 632
Metadata
- Authors
- Gordon, M. S., & Cunningham, D.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 69
- Issue
- Suppl. 3
- Pages
- 25-33
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2052066839
- Cited by
- 283
- References
- 29
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.